乾癬性關節炎治療市場規模、佔有率和成長分析：按藥物類別、給藥途徑、治療階段、分銷管道和地區分類－2026-2033年產業預測

2024 年全球乾癬性關節炎治療市場價值為 125.2 億美元，預計到 2033 年將從 2025 年的 133.9 億美元成長至 228.5 億美元，預測期（2026-2033 年）的複合年成長率為 6.92%。

乾癬性關節炎治療市場正經歷顯著成長，這主要得益於公眾意識的提高以及創新治療方法的湧現，這些療法正在重新定義治療方法。關鍵市場細分領域包括生物製藥、透過保險增強的自付費用支援、學名藥的普及以及非藥物療法，例如職業療法和物理療法。從傳統的緩解疾病抗風濕藥物（DMARDs）轉向先進的TNF-α抑制劑和IL-17/IL-23生物製劑，正在拓展治療選擇並提高患者依從性。診斷技術的進步和醫療保險政策的不斷改進對這一成長至關重要，因為它們有助於患者儘早獲得標靶治療。此外，肌肉骨骼成像技術的進步和口服JAK抑制劑的引入進一步豐富了治療策略，並使製造商能夠投資於患者支持和真實世界數據（REW）計畫。

全球乾癬性關節炎治療市場的成長要素

由於生物製藥領域的最新創新，全球乾癬性關節炎治療市場正經歷顯著成長。這些創新拓展了治療選擇，並改善了患者的臨床療效。這項進展增強了醫療專業人員推薦標靶治療的信心。生物製藥的療效和個人化作用機制正推動其在專科醫生中的廣泛應用，並促進持續的研發。此外，生技公司與醫療機構之間日益密切的合作促成了治療指南的更新，並提高了人們對這些創新治療方法價值的認知。這些趨勢正在推動市場投資，促使新藥上市，並擴大門診和住院患者的治療途徑。

全球乾癬性關節炎治療市場面臨的限制因素

先進治療方法的高昂費用不僅嚴重阻礙了病患的就醫，也加重了醫療預算的負擔。這往往導致保險公司採取嚴格的報銷政策，並要求事先核准，可能阻礙患者堅持治療方案。此外，經濟負擔也可能使醫療專業人員在提案這些昂貴治療方法時猶豫不決，尤其是在資源匱乏的環境中，並可能延遲將新治療方法納入醫療保險範圍。這些經濟障礙限制了潛在市場規模，使製藥公司的市場准入策略更加複雜，最終阻礙了臨床有效治療方法的推廣應用，即便這些療法已經存在，從而限制了整體市場成長。

全球乾癬性關節炎治療市場趨勢

全球乾癬性關節炎治療市場正日益受到精準醫療趨勢的影響，精準醫療專注於針對個別患者特徵量身定做的分子標靶療法。這一趨勢凸顯了基於生物標記的患者分層的重要性，有助於根據每位患者的疾病特異性機制調整治療方案。診斷和製藥領域相關人員之間的合作正在改進臨床試驗設計，並建立以價值為導向的報銷支援體系。因此，醫療服務提供者越來越重視個人化治療方法，旨在提高治療反應的預測準確性，摒棄試驗誤式處方，增強患者依從性和臨床療效，並最大限度地減少不利事件。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球乾癬性關節炎治療市場規模：依藥物類別分類

• TNF抑制劑
• IL-17抑制劑
• IL-12/23抑制劑
• JAK抑制劑
• PDE4抑制劑

全球乾癬性關節炎治療市場規模：依治療途徑分類

• 注射藥物
• 口服

全球乾癬性關節炎治療市場規模：依治療階段分類

• 一線治療
• 二級治療

全球乾癬性關節炎治療市場規模：按分銷管道分類

• 醫院藥房
• 專科藥房
• 線上

全球乾癬性關節炎治療市場規模：按地區分類

• 北美洲
• 歐洲
• 亞太地區

全球乾癬性關節炎治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• AbbVie Inc.（Humira, Rinvoq）
• Johnson & Johnson（Tremfya, Simponi）
• Pfizer Inc.（Enbrel, Xeljanz）
• Novartis AG（Cosentyx, Taltz co-marketed）
• Eli Lilly（Taltz）
• UCB SA（Cimzia）
• Bristol Myers Squibb（Orencia）
• Amgen Inc.（Enbrel co-marketed）
• Biogen（Otezla partnership）
• Celgene/BMS（Otezla）
• Sun Pharmaceutical
• Merck & Co.
• AstraZeneca
• Boehringer Ingelheim
• Galapagos NV
• Gilead Sciences（Filgotinib）
• Moonlake Immunotherapeutics
• Acelyrin Inc.
• Sonoma Biotherapeutics
• Affibody AB

結論與建議

Global Psoriatic Arthritis Treatment Market size was valued at USD 12.52 Billion in 2024 and is poised to grow from USD 13.39 Billion in 2025 to USD 22.85 Billion by 2033, growing at a CAGR of 6.92% during the forecast period (2026-2033).

The psoriatic arthritis treatment market is experiencing significant growth driven by heightened awareness and the emergence of innovative therapies that have redefined treatment methodologies. Key market segments include biologics, enhanced copay assistance through insurance, increased access to generics, and non-drug therapies like occupational and physical therapy. The shift from traditional Disease Modifying Anti-Rheumatic Drugs (DMARDs) to advanced TNF-alpha inhibitors and IL-17 or IL-23 biopharmaceuticals has broadened treatment options and fostered improved patient compliance. Factors like refined diagnostic techniques and evolving reimbursement policies are pivotal in this growth, as they facilitate earlier access to targeted therapies. Additionally, advancements like musculoskeletal imaging and the introduction of oral JAK inhibitors have further diversified treatment strategies, enabling manufacturers to invest in patient support and real-world evidence initiatives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psoriatic Arthritis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psoriatic Arthritis Treatment Market Segments Analysis

Global psoriatic arthritis treatment market is segmented by drug class, route, line of therapy, distribution and region. Based on drug class, the market is segmented into TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, JAK inhibitors and PDE4 inhibitors. Based on route, the market is segmented into injectable and oral. Based on line of therapy, the market is segmented into first-line and second-line. Based on distribution, the market is segmented into hospital pharmacies, specialty pharmacies and online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psoriatic Arthritis Treatment Market

The global psoriatic arthritis treatment market is experiencing significant growth due to recent innovations in biologic therapies, which have expanded treatment options and enhanced clinical outcomes for patients. This progress has instilled greater confidence in healthcare professionals regarding the recommendation of targeted therapies. The effectiveness and tailored mechanisms of biologics have encouraged their widespread adoption among specialists, spurring ongoing research and development. Additionally, partnerships between biotechnology firms and healthcare providers have flourished, resulting in updated treatment guidelines and a heightened perception of the value offered by these innovative therapies. Such developments are driving market investment, introducing new agents, and expanding treatment access in both outpatient and hospital settings.

Restraints in the Global Psoriatic Arthritis Treatment Market

The elevated costs associated with advanced therapies are posing significant challenges for patient access while straining healthcare budgets. This situation often leads payers to adopt restrictive reimbursement policies and require prior authorizations, which can deter patients from adhering to treatment regimens. The financial burden may also discourage healthcare professionals from proposing these costly options, especially in under-resourced environments, and delay the inclusion of new treatment options in formularies. Such economic barriers restrict the potential market size, complicate access strategies for manufacturers, and ultimately hinder the rate of adoption despite the availability of clinically effective treatments, thereby constraining overall market growth.

Market Trends of the Global Psoriatic Arthritis Treatment Market

The Global Psoriatic Arthritis Treatment market is increasingly influenced by the shift towards precision medicine, focusing on molecularly targeted therapies that cater to individual patient profiles. This trend underscores the importance of biomarker-based patient stratification, facilitating the alignment of specific therapeutic agents with the unique mechanisms of each patient's disease. Collaboration among diagnostic and pharmaceutical stakeholders is enhancing the design of clinical trials and supporting systems that prioritize value-based reimbursement. Consequently, healthcare providers are leaning towards personalized treatment regimens, aiming to reduce trial-and-error prescribing while improving patient adherence, clinical outcomes, and minimizing adverse events through better predictability in therapeutic responses.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Psoriatic Arthritis Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• TNF Inhibitors
• IL-17 Inhibitors
• IL-12/23 Inhibitors
• JAK Inhibitors
• PDE4 Inhibitors

Global Psoriatic Arthritis Treatment Market Size by Route & CAGR (2026-2033)

• Market Overview
• Injectable
• Oral

Global Psoriatic Arthritis Treatment Market Size by Line of Therapy & CAGR (2026-2033)

• Market Overview
• First-Line
• Second-Line

Global Psoriatic Arthritis Treatment Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Online

Global Psoriatic Arthritis Treatment Market Size by Region & CAGR (2026-2033)

• Market Overview
• North America
• Europe
• Asia-Pacific

Global Psoriatic Arthritis Treatment Market Size & CAGR (2026-2033)

• North America (Drug Class, Route, Line of Therapy, Distribution, Region)
  • US
  • Canada
• Europe (Drug Class, Route, Line of Therapy, Distribution, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route, Line of Therapy, Distribution, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route, Line of Therapy, Distribution, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route, Line of Therapy, Distribution, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (Humira, Rinvoq)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Tremfya, Simponi)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (Enbrel, Xeljanz)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Cosentyx, Taltz co-marketed)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (Taltz)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB SA (Cimzia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (Orencia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (Enbrel co-marketed)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (Otezla partnership)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene/BMS (Otezla)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galapagos NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (Filgotinib)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moonlake Immunotherapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acelyrin Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sonoma Biotherapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Affibody AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations